Screener
Opus Genetics IRD Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Assets | As of / March 31,2026 / (Unaudited) | As of / December 31,2025 |
|---|---|---|
| Accrued expenses | 4,918 | 4,488 |
| Total current liabilities | 9,340 | 7,781 |
| Warrant liabilities | 77,349 | 25,985 |
| Funding agreement, related party | 1,198 | 1,129 |
| Total liabilities | 87,887 | 34,895 |
| Commitments and contingencies (Note 3 and Note 9) | ||
| Series B preferred stock, par value $0.0001; 7,374,632 shares and no shares were designated as of March 31, 2026 and December 31, 2025, respectively; 7,374,632 shares and no shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. | 24,736 | — |
| Stockholders’ (deficit) equity: |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's long-term debt?
- Opus Genetics (IRD) reported long-term debt of $1.2M in Q1 2026.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Opus Genetics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude